This is a lung disease where the lung tissue becomes scarred and stiff, making it hard to breathe. The cause is unknown. It usually affects older adults and causes shortness of breath and a dry cough.
Every report comes from a Lived member, sent anonymously.
Have you tried Home oxygen therapy for Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease in which the tissue around the lungs' tiny air sacs gradually thickens and scars. "Pulmonary fibrosis" means scarring of the lungs, and "idiopathic" means no cause can be found. Scarred lung tissue is stiff, so each breath takes more effort, and oxygen has a harder time passing from the air sacs into the blood. The usual first signs are shortness of breath that builds slowly, at first only with exertion such as climbing stairs, and a dry cough that does not go away. Some people also notice tiredness, unintended weight loss, aching muscles and joints, or clubbing, a widening and rounding of the fingertips. IPF mainly affects people in their 60s and 70s, and it usually worsens over time. IPF is one type of interstitial lung disease, a large group of conditions that inflame or scar the lungs. Many of the others have an identifiable cause, such as an autoimmune disease, a medicine, or inhaled dust or mold. The difference matters because treatment and outlook vary, and IPF is diagnosed only after those causes have been looked for.
No one knows exactly why IPF starts. The leading explanation is that the lining of the air sacs is injured again and again, and the normal repair process goes wrong, laying down scar tissue instead of healthy tissue. What sets off that cycle in a particular person usually cannot be identified. Several factors make IPF more likely. Age is the clearest: it is most often diagnosed in people in their 60s and 70s, and it is more common in men than in women. Cigarette smoking, now or in the past, is common among people who develop it, and long-term exposure to metal dust has also been linked to higher risk. These are associations, not causes in an individual case, and most people with these exposures never develop IPF. Genes play a part as well. Having a parent, brother or sister with IPF raises risk, and changes in more than 10 genes have been linked to the disease, including genes involved in lung mucus and in protecting a cell's genetic material as it divides. When several relatives are affected, a doctor may suggest genetic testing and checking other family members for early signs.
Because IPF is defined by having no known cause, diagnosis largely means ruling out other explanations for lung scarring. A clinician asks about symptoms, smoking, jobs and hobbies (for example, exposure to asbestos, metal dust, birds or mold), medicines and family history, and checks for autoimmune diseases such as rheumatoid arthritis or scleroderma, often with blood tests. Listening to the chest frequently reveals fine crackles at the bottom of the lungs, a sound often compared to Velcro being pulled apart. The central test is a high-resolution CT (HRCT) scan, a detailed CT of the chest. In IPF, scarring typically follows a recognizable pattern called usual interstitial pneumonia (UIP): it is heaviest at the outer edges and bases of the lungs, sometimes with clusters of small cysts that look like a honeycomb. When the scan shows this pattern and the rest of the evaluation fits, the diagnosis can be made without a biopsy. The same pattern can appear in other conditions, which is why the history and blood tests still matter. Breathing tests show how much the scarring is affecting the lungs. A key number is forced vital capacity (FVC), the amount of air a person can blow out after the deepest possible breath. Results are reported as a percentage of what is expected for someone of the same age, sex and height. A lower percentage means the lungs hold less air, and a falling FVC over time is one of the main signs the disease is advancing. A diffusion test shows how well oxygen moves into the blood, and a 6-minute walk test shows how activity affects breathing and oxygen. When the scan is not conclusive, a small sample of lung tissue may be needed. It can be taken by keyhole surgery or, in centers with experience, through a flexible tube passed into the airways (a cryobiopsy). Lung specialists, radiologists and pathologists often review the findings together, because no single test settles the diagnosis.
There is currently no cure for IPF, and scarring that has already formed cannot be reversed. Treatment aims to slow further scarring, ease symptoms, keep people active and plan for the future. Three prescription pills are approved in the US to slow the disease. Nintedanib (Ofev) and pirfenidone (Esbriet, also sold as a generic) are antifibrotic medicines, meaning they damp down the scarring process. Nerandomilast (Jascayd), approved in 2025, works differently (it blocks an enzyme called phosphodiesterase 4) and was studied both on its own and in people already taking one of the other two. In clinical trials, each one slowed the yearly loss of lung function measured by FVC compared with a placebo. None of them makes breathing feel easier or restores lost lung function. The benefit is that the decline is slower than it would otherwise be, which is real but hard to feel day to day. Side effects often shape the choice. Nintedanib commonly causes diarrhea, nausea and vomiting, and it can harm a developing baby, so it is not used during pregnancy and effective contraception is needed. Pirfenidone commonly causes nausea, loss of appetite and a rash that is triggered by sunlight, so daily sun protection is part of taking it. Both can affect the liver, so liver blood tests are done before starting and regularly afterward. Nerandomilast commonly causes diarrhea, and depression, weight loss and reduced appetite were also reported in its trials. Lowering the dose or pausing for a while often makes side effects manageable. Other care makes a large difference to daily life. Supplemental oxygen helps people whose oxygen level drops at rest, with activity or during sleep, and can ease breathlessness and make exercise possible. Pulmonary rehabilitation, a supervised program of exercise training and education about breathing and pacing, does not slow the scarring but helps people do more with less breathlessness. Stopping smoking and treating related problems, such as acid reflux, sleep apnea and high blood pressure in the lungs (pulmonary hypertension), are also part of care. A lung transplant is the only treatment that replaces scarred lungs. It is an option for some people who are otherwise healthy enough for major surgery, and guidelines recommend referring people at higher risk early, even at diagnosis, so evaluation is not left too late. It brings its own demands, including lifelong anti-rejection medicine and a risk of infection and rejection. Palliative care, which focuses on relieving cough, breathlessness and anxiety, can be added alongside any of these treatments.
IPF gets worse over time for most people, but its pace is hard to predict. Some people stay stable for years, while others decline over months. Breathlessness that first appears on hills or stairs tends to spread to everyday tasks such as dressing or showering, and some people eventually need oxygen at rest. Over time, IPF can lead to respiratory failure, when the lungs can no longer supply enough oxygen, and it puts strain on the right side of the heart. It is a serious illness that often shortens life, which is why planning ahead matters even while someone feels fairly well. Some people have acute exacerbations: a sudden worsening over days or a few weeks, sometimes with no clear trigger. These can be life threatening, are more common in advanced disease, and may happen more than once. People with IPF also have a higher risk of lung cancer, which follow-up scans watch for. Follow-up usually means seeing a lung specialist every three to six months, with breathing tests and walk tests to track change, plus liver blood tests for anyone taking an antifibrotic. These results guide decisions about medicines, oxygen and transplant referral. Day to day, regular activity such as walking helps maintain strength; smaller, more frequent meals can ease the breathlessness a full stomach brings; and avoiding smoke, dust, high altitude and days of poor air quality can help. Living with a progressive lung disease often brings anxiety and low mood. Counseling, treatment for depression and support groups for people with pulmonary fibrosis can help, as can involving family early. Talking about goals, transplant and advance care planning while symptoms are milder lets people make their own choices.
See a doctor if shortness of breath with activity has been building over months, or a dry cough has lasted more than a few weeks, especially if you are over 50, have smoked, or have a relative with pulmonary fibrosis. If you have IPF, contact your care team right away if breathing becomes harder, faster or shallower over days or weeks, you need to lean forward when sitting to breathe comfortably, you have a fever or cough up dark mucus, or you develop frequent headaches. A sudden change like this can be an acute exacerbation or an infection, and early assessment matters. Also contact your prescriber promptly about dark urine or yellowing of the skin or eyes while taking an antifibrotic, since these can signal a liver problem. Call 911 for severe trouble breathing, such as struggling for breath at rest or being unable to speak in full sentences, or if breathing difficulty comes with bluish lips or fingertips, confusion or unusual sleepiness.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Idiopathic Pulmonary Fibrosis is like, what's helped you, or ask the community a question.